Company: PSTV
Filing Date: 2025-04-01
Form Type: PRER14A
Source: 0001140361-25-011649
Chunk: 36

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-01
Form: PRER14A
Chunk 36
---
,902 |     | *                      |
| Howard Clowes(3)            |     |               9,804 |     | *                      |
| Richard J. Hawkins(4)       |     |               4,902 |     | *                      |
| Greg Petersen(5)            |     |              12,255 |     | *                      |
| Robert P. Lenk, PhD(6)      |     |               4,167 |     | *                      |

| * | Less than 1%. |

| (1) | Dr. Hedrick is the President, Chief Executive Officer and a director of the Company. |

| (2) | Mr. Sims is the Chief Financial Officer of the Company. |

| (3) | Mr. Clowes is a director of the Company. |

| (4) | Mr. Hawkins is the Chairman of the Board of the Company. |

| (5) | Mr. Petersen is a director of the Company. |

| (6) | Dr. Lenk is a director of the Company. |

Required Vote of Stockholders Approval of Proposal No. 4 requires the affirmative vote of a majority of the Common Stock having voting power present, virtually or by proxy. Abstentions are considered shares present and entitled to vote and thus will have the effect of a vote “AGAINST” this proposal. Broker non-votes will have no effect on the results of this vote. Board Recommendation OUR BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THIS PROPOSAL NO. 4 TO APPROVE, FOR PURPOSES OF COMPLYING WITH NASDAQ LISTING RULE 5635(D) AND THE REQUIREMENTS OF THE SPEA, OF THE WARRANT AMENDMENT PROPOSAL.

21

#### TABLE OF CONTENTS

#### PROPOSAL 5: ADJOURNMENT PROPOSAL
In addition to the Reverse Stock Split Proposal, the Issuance Proposal, the Authorized Common Stock Increase Proposal and the Warrant Amendment Proposal, our stockholders are also being asked to approve one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies in favor of any or all of the Reverse Stock Split Proposal and the Issuance Proposal, if there are insufficient votes at the time of such adjournment to approve and adopt any or all of the Reverse Stock Split Proposal, the Issuance Proposal, the Authorized Common Stock Increase Proposal or